Evaluation of the effect of trastuzumab in the treatment ofbreast cancer

Breast cancer is caused by the Irregular growth of abnormal cells in thebreast. Trastuzumab is one of the drugs used to treat breast cancer. It is apotent anti-inflammatory of breast cancer and a new monoclonal antibodyWhich promotes the growth-promoting protein HER۲ suppresses.Trastuzumab and pertuzumab, which are human monoclonal antibodies incombination with chemotherapy, are known as the primary line of treatmentfor metastatic cancers, including breast cancer. In contrast, trastuzumab andlapatinib, which suppress human epidermal growth factors, have beenidentified as the next line of treatment. Resistance to trastuzumab is a majorbarrier to the treatment of HER۲-positive breast cancer. Decreased expressionmir۱۴۱ in cancer cells is one of the mechanisms of resistance to trastuzumab.The present study aimed to investigate the effect of trastuzumab (Herceptin)on the treatment of breast cancer.The results show that trastuzumab has positive prospects in the treatment ofbreast cancer. However, a large percentage of patients still do not respond totreatment despite persistent antigen expression against monoclonalantibodies. Due to overexpression of extracellular matrix components thatblock HER۲ as a barrier and do not allow drug access to the receptor .What isclear is that this complication gets worse over time But targeted treatment canprevent metastasis and the risk of recurrence. For this reason, it isrecommended that prevention and treatment be taken in case of anysymptoms.

کلیدواژه ها:

Breast cancer ، Trastuzumab ، Monoclonal antibody ، mir۱۴۱